(Q44540053)

4 December 2017

Patients at high risk for CMV infection and disease show delayed CD8+ T-cell immune recovery after allogeneic stem cell transplantation (English)

1 reference

4 December 2017

Ganepola S

1

1 reference

4 December 2017

Gentilini C

2

1 reference

4 December 2017

Hilbers U

3

1 reference

4 December 2017

Lange T

4

1 reference

4 December 2017

Rieger K

5

1 reference

4 December 2017

Hofmann J

6

1 reference

4 December 2017

Maier M

7

1 reference

4 December 2017

Liebert UG

8

1 reference

4 December 2017

Niederwieser D

9

1 reference

4 December 2017

Engelmann E

10

1 reference

4 December 2017

Heilbronn R

11

1 reference

4 December 2017

Thiel E

12

1 reference

4 December 2017

Uharek L

13

1 reference

4 December 2017

language of work or name

English

0 references

publication date

29 January 2007

1 reference

Bone Marrow Transplantation

4 December 2017

1 reference

4 December 2017

39

1 reference

4 December 2017

5

1 reference

4 December 2017

293-299

1 reference

https://scigraph.springernature.com/pub.10.1038/sj.bmt.1705585

4 December 2017

0 references

cites work

Cytomegalovirus in hematopoietic stem cell transplant recipients: current status, known challenges, and future strategies

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705585

7 January 2021

Donor CMV serologic status and outcome of CMV-seropositive recipients after unrelated donor stem cell transplantation: an EBMT megafile analysis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705585

7 January 2021

Late cytomegalovirus disease and mortality in recipients of allogeneic hematopoietic stem cell transplants: importance of viral load and T-cell immunity

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705585

7 January 2021

Increased risk of complicated CMV infection with the use of mycophenolate mofetil in allogeneic stem cell transplantation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705585

7 January 2021

Clinical aspects of CMV infection after stem cell transplantation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705585

7 January 2021

Risk factors for cytomegalovirus reactivation after CD6+ T-cell-depleted allogeneic bone marrow transplantation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705585

7 January 2021

Cytomegalovirus infections in allogeneic stem cell recipients after reduced-intensity or myeloablative conditioning assessed by quantitative PCR and pp65-antigenemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705585

7 January 2021

Prevention of cytomegalovirus disease in hematopoietic stem cell transplantation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705585

7 January 2021

Cytotoxic T cells specific for cytomegalovirus: a potential therapy for immunocompromised patients

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705585

7 January 2021

Clinical trials with CMV-specific T cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705585

7 January 2021

Definitions of cytomegalovirus infection and disease in transplant recipients

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705585

7 January 2021

Incidence and outcome of cytomegalovirus infections following nonmyeloablative compared with myeloablative allogeneic stem cell transplantation, a matched control study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705585

7 January 2021

Patient cytomegalovirus seropositivity with or without reactivation is the most important prognostic factor for survival and treatment-related mortality in stem cell transplantation from unrelated donors using pretransplant in vivo T-cell depletion

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705585

7 January 2021

Tetramer-based quantification of cytomegalovirus (CMV)-specific CD8+ T lymphocytes in T-cell-depleted stem cell grafts and after transplantation may identify patients at risk for progressive CMV infection

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705585

7 January 2021

Different kinetics in anti-cytomegalovirus immunity reconstitution evaluated by lymphocyte proliferation and IFN-gamma production in allogeneic and autologous bone marrow transplantation.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705585

7 January 2021

Enumerating antigen-specific T-cell responses in peripheral blood: a comparison of peptide MHC Tetramer, ELISpot, and intracellular cytokine analysis.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705585

7 January 2021

Surveillance of cytomegalovirus infection in haematopoietic stem cell transplantation patients

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705585

7 January 2021

Whole blood real-time quantitative PCR for cytomegalovirus infection follow-up in transplant recipients.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705585

7 January 2021

Reconstitution of CD8 T cells is essential for the prevention of multiple-organ cytomegalovirus histopathology after bone marrow transplantation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705585

7 January 2021

Two subsets of memory T lymphocytes with distinct homing potentials and effector functions

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705585

7 January 2021

Management of CMV infections: recommendations from the infectious diseases working party of the EBMT.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705585

7 January 2021

Risk factors for treatment failures in patients receiving PCR-based preemptive therapy for CMV infection

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705585

7 January 2021

Protection from cytomegalovirus after transplantation is correlated with immediate early 1-specific CD8 T cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705585

7 January 2021

Identifiers

DOI

10.1038/SJ.BMT.1705585

1 reference

4 December 2017

1 reference